Harvard Bioscience Inc
HBIO· Nasdaq
HBIOHarvard Bioscience Inc
Released Mar 8, 2022, before the open
10-K filed Mar 11, 2022, 70 days after period end · 0001171843-22-001806
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $33.06M | $30.98M | $30.97M | $33.86M |
| Net Income | $961.00K | -$615.00K | $550.00K |
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR
| $2.86M |
| EPS Diluted | — | — | $0.02 | $0.08 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
